Showing 13 to 20 of 20 results
Weight-Loss Drugs Show Promise in Treating Multiple Diseases, but Risks Remain
A Nature Medicine study shows weight-loss drugs like Wegovy and Ozempic effectively treat various diseases by reducing obesity and inflammation, potentially lowering Alzheimer's risk by 12%, but also carry risks of gastrointestinal issues, hypotension, and kidney problems.
Weight-Loss Drugs Show Promise in Treating Multiple Diseases, but Risks Remain
A Nature Medicine study shows weight-loss drugs like Wegovy and Ozempic effectively treat various diseases by reducing obesity and inflammation, potentially lowering Alzheimer's risk by 12%, but also carry risks of gastrointestinal issues, hypotension, and kidney problems.
Progress
24% Bias Score
Weight-Loss Drugs Double Pancreatitis Risk: Major Study
A Washington University study of over 2 million diabetes patients found that weight-loss drugs like Ozempic doubled the risk of pancreatitis and increased risks of nausea/vomiting (30%), arthritis (11%), headaches (10%), and sleep disturbances (12%), despite also showing benefits in cardiovascular a...
Weight-Loss Drugs Double Pancreatitis Risk: Major Study
A Washington University study of over 2 million diabetes patients found that weight-loss drugs like Ozempic doubled the risk of pancreatitis and increased risks of nausea/vomiting (30%), arthritis (11%), headaches (10%), and sleep disturbances (12%), despite also showing benefits in cardiovascular a...
Progress
52% Bias Score
NHS Weight-Loss Jab: High Cost Limits Access for Millions
Ray, 62, lost over two stone in five months using Wegovy via the NHS, but limited funding means only a tiny percentage of the 3.4 million eligible patients in England can access such treatments; the annual cost per patient is around £3,000.
NHS Weight-Loss Jab: High Cost Limits Access for Millions
Ray, 62, lost over two stone in five months using Wegovy via the NHS, but limited funding means only a tiny percentage of the 3.4 million eligible patients in England can access such treatments; the annual cost per patient is around £3,000.
Progress
52% Bias Score
Weight-Loss Drugs: Economic Benefits and NHS Strain
Two weight-loss injections, Wegovy and Monjaro, are showing promise in helping obese people lose weight and return to work, but their increased use strains the NHS and raises concerns about long-term effects and equitable access.
Weight-Loss Drugs: Economic Benefits and NHS Strain
Two weight-loss injections, Wegovy and Monjaro, are showing promise in helping obese people lose weight and return to work, but their increased use strains the NHS and raises concerns about long-term effects and equitable access.
Progress
36% Bias Score
Weight-Loss Drugs Show Reduced Alzheimer's Risk, But Increased Gastrointestinal Issues
A study of over two million US diabetic patients found that GLP-1 receptor agonist weight-loss drugs like Wegovy and Ozempic reduced the risk of Alzheimer's by 12%, drug/alcohol dependence, and some blood clotting issues, but increased risks of gastrointestinal problems, low blood pressure, and kidn...
Weight-Loss Drugs Show Reduced Alzheimer's Risk, But Increased Gastrointestinal Issues
A study of over two million US diabetic patients found that GLP-1 receptor agonist weight-loss drugs like Wegovy and Ozempic reduced the risk of Alzheimer's by 12%, drug/alcohol dependence, and some blood clotting issues, but increased risks of gastrointestinal problems, low blood pressure, and kidn...
Progress
32% Bias Score
Global Report Advocates for Redefined Obesity Classification
A global report calls for a new definition of obesity, differentiating between "clinical obesity" (with health problems) and "pre-clinical obesity" (without), advocating for personalized treatments and highlighting concerns about healthcare funding.
Global Report Advocates for Redefined Obesity Classification
A global report calls for a new definition of obesity, differentiating between "clinical obesity" (with health problems) and "pre-clinical obesity" (without), advocating for personalized treatments and highlighting concerns about healthcare funding.
Progress
56% Bias Score
Lilly Intervenes in Lawsuit over Compounded Tirzepatide Drugs
Eli Lilly joined a lawsuit against the FDA, contesting the agency's October 2023 decision ending the shortage designation for its tirzepatide-based drugs (Zepbound and Mounjaro), impacting the legality of cheaper compounded alternatives. The FDA affirmed its decision in December, but the compounding...
Lilly Intervenes in Lawsuit over Compounded Tirzepatide Drugs
Eli Lilly joined a lawsuit against the FDA, contesting the agency's October 2023 decision ending the shortage designation for its tirzepatide-based drugs (Zepbound and Mounjaro), impacting the legality of cheaper compounded alternatives. The FDA affirmed its decision in December, but the compounding...
Progress
36% Bias Score
NHS Weight-Loss Drug Debate
A survey reveals high interest in free anti-obesity drugs on the NHS, sparking debate about the role of medication in combating obesity and its potential economic implications.
NHS Weight-Loss Drug Debate
A survey reveals high interest in free anti-obesity drugs on the NHS, sparking debate about the role of medication in combating obesity and its potential economic implications.
Progress
36% Bias Score
Showing 13 to 20 of 20 results